Malignant ascites is a common problem in patients with advanced malignancies and peritoneal spread of tumour. Treatment strategies include paracentesis, diuretics and peritoneovenous shunts; however, there are no established evidence-based guidelines for optimal therapy. Th is review is intended to add clarity to the current procedures for the management of malignant ascites, and furthermore discusses new promising approaches.
Introduction
Malignant ascites is a common problem in advanced neoplasms and occurs especially in association with breast, bronchus, ovary, stomach, pancreas and colorectal cancer [1] . Up to 20% of all patients with malignant ascites have tumours of unknown primary origin [1, 2] . Th e onset and progression of malignant ascites is associated with a rapid deterioration in quality of life and a poor prognosis. Overall survival is mainly determined by the origin of the primary cancer. Patients with ovarian cancer have a better prognosis while patients with malignant ascites of gastrointestinal origin or unknown origin have the worst outcome [3] . Large amounts of ascites can induce increased abdominal pressure and thereby cause discomfort and distress with symptoms such as abdominal pain (53%), nausea (37%), anorexia (36%), vomiting (25%), fatigue (17%), dyspnoea (11%) and early fullness (6%) [3] . Especially in end stage disease treatment is aimed at improving quality of life by achieving symptom relief with minimal invasive techniques that at the same time have the lowest risk for complications.
Pathophysiology and diagnosis
Pathophysiology of malignant ascites is multifactorial and yet incompletely understood. In addition to decreased lymphatic drainage and hormonal mechanisms cytokinemediated increased capillary permeability is discussed to play a role, since malignant ascites is usually protein-rich [4] . Mediators such as vascular endothelial growth factor (VEGF), interleukin-6 and tumour necrosis factor may play a role as well [5] . In individual cases hypoalbuminemia due to impaired liver function second to liver metastases or portal hypertension caused by large liver tumours occluding portal or hepatic veins may contribute to ascites as well. After diagnosis by physical examination and imaging malignant ascites is usually confi rmed by diagnostic paracentesis. Cytological analysis is the most specifi c test to demonstrate malignant ascites. It is about 97% sensitive with peritoneal carcinomatosis [6] , but is poor in detecting other types of malignant ascites. Cell counts with a diff erential are useful in the presumptive diagnosis of bacterial peritonitis, particularly if the neutrophil count is greater than 250 cells per ml. Nevertheless peritoneal carcinomatosis can mimic spontaneous bacterial peritonitis. If infection is suspected, a Gram stain and culture should be performed. Th e serum-ascites albumin gradient (SAAG) is recommended for the diff erential diagnosis and management of ascites. SAAG is calculated by subtracting the ascitic fl uid albumin level from the serum level obtained on the same day. A gradient of more than 1.1 g/ dL indicates presence of portal hypertension, a decreased gradient (<1.1 g/dL) is found in peritoneal carcinomatosis [7] . Additional imaging (e.g. Doppler ultrasound of the portal vein) may help to specify the cause of ascites in individual cases.
Therapeutic options
Surveys of practices in management of malignant ascites from England [3] and Canada [8] show that paracentesis, diuretics and systemic chemotherapy against the underlying malignancy are commonly used procedures. Peritoneovenous shunts, cytoreductive surgery and (hyperthermic) intraperitoneal (i.p.) chemotherapy are used as well. However, in contrast to the well-established guidelines for treatment of the origin of the primary cancer, there are no evidence-based guidelines for optimal therapy of malignant ascites. Current approaches are mainly based on personal experience and adapted from the treatment of cirrhosis-associated ascites. 
Therapeutic paracentesis and permanent drains
In about 90% of patients therapeutic paracentesis yields good, although temporary relief of symptoms. A review of studies showed no consensus on the rate or maximum volume of fl uid withdrawal. Reported complications are infrequent and include hypotension, pulmonary embolism, secondary peritonitis and perforation. Severe hypotension and renal impairment might be reduced by concurrent volume expansion. Studies in patients with cirrhosis-associated ascites showed that in paracentesis of large volume albumin is superior to other plasma expanders in preventing circulatory dysfunction. Th erefore, infusion of albumin (e.g., 6-8 g per liter of ascites removed) has been used concurrent to paracentesis of malignant ascites. However, the need for colloid replacement remains controversial since in the context of malignant ascites no trials have been performed. Clinical experience suggests that intravenous albumin infusion is not generally necessary. In a retrospective analyses of 30 paracenteses in 12 patients with malignant ascites up to 5 L fl uid could be withdrawn and intravenous fl uids were only given when specifically indicated. Th ere was no case of symptomatic hypotension and blood products or intravenous fl uids were given in only 6 cases [9] . According to a prospective study observing 48 paracenteses in 44 patients, a mean withdrawal of 5.3 L (range 0.8-15 L, median 4.9 L) is needed in order to achieve a significant symptom relief [10] . No severe side eff ects were reported and patients did not require volume expansion.
If serial paracentesis does not yield fl uid control permanent drains can be considered. For non-tunnelled catheters (e.g. pigtail catheter) a complication rate of up to 30% has been reported, including infection, sepsis and occlusion. In contrast, a retrospective series of 40 tunnelled catheters reported low complication rates which were comparable to repeated large volume paracentesis in 67 patients [11] .
Diuretic treatment
Diuretics are often used in the management of malignant ascites [7] , despite their use being highly controversial. Th ere are no randomised controlled trials on effi cacy or eff ectiveness.
Becker and colleagues evaluated 5 studies including 113 patients with diff erent tumours and found diuretics to be successful in approximately 43% [12] . However, phase II data [13] suggest that response to diuretics is restricted to patients with a SAAG >1.1 g/dL (congruent to benign ascites due to liver cirrhoses), whereas malignant ascites with a SAAG <1.1 g/dL is highly resistant to diuretic use. Some authors even state that medical therapies, such as diuretics as well as sodium and fl uid restriction, are not eff ective in most oncological patients independent from SAAG [14] . It has to be emphasized that patients and doctors should be aware of possible side eff ects such as hypovolemia and renal failure when using diuretics.
Octreotide
Somatostatin and octreotide are often used successfully to treat diarrhoea and lymphatic leakage due to abdominal and thoracic surgery. Case reports suggest that subcutaneous octreotide is also eff ective in the management of chylous ascites in malignant disease [15] . Data from a Phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating the effi cacy in a broad range of tumours which started in 2005 are pending.
Peritoneovenous shunts
Initially developed for use in patients with refractory ascites due to liver cirrhoses peritoneovenous shunts subsequently became popular in the management of malignant ascites in Anglo-American countries. Relevant contraindications are loculated ascites, portal hypertension, coagulation disorders, and advanced cardiac or renal impairment. Furthermore due to higher risk of shunt occlusion haemorrhagic ascites and fl uid protein content >4.5 g/L are considered as contraindications to shunt placement. Patients with ovarian and breast cancers who undergo peritoneovenous shunting have the best response rates (>50%) compared to gastrointestinal cancers (10-15%) [4] . Reported side eff ects include pulmonary oedema or embolism, subclinical as well as clinically relevant disseminated intravascular coagulation, and infection. Th ese complications have to be expected in about 6% of patients [12] . Even though systemic dissemination of malignant cells is theoretically obligatory, postmortem analysis proved this concern to be clinically insignifi cant [4] . However, shunting is not an established procedure in managing malignant ascites in Europe, possibly due to balancing benefi t and potential risks diff erentially.
Transjugular intrahepatic portosystemic shunt
For patients with cirrhosis and refractory ascites who have relatively good hepatic and renal function, transjugular intrahepatic portosystemic shunt (TIPS) is considered the treatment of choice. In two cases of malignant portal and hepatic vein occlusion, TIPS improved ascites and quality of life [16] . Th us in selected cancer patients with metastatic disease to the liver or locally advanced cancer, e.g. biliary cancer, TIPS can be considered. As with any palliative management option, the decision to pursue invasive procedures is dependent on the patient's goals in the context of the disease.
Intraperitoneal chemotherapy and cytoreductive surgery
Th e intent of i.p. therapy in malignant ascites is usually palliative. I.p. chemotherapy as well as hyperthermic i.p. chemotherapy (HIPEC), which is proven to have enhanced cytotoxicity, have been investigated in small series and must be considered experimental [17] .
Th e objective of cytoreductive surgery in combination with HIPEC is to remove all macroscopic tumour after abdominal exploration leaving only microscopic residual disease for improved tumour tissue penetration with HIPEC [18] . Th is multimodal approach has been shown to improve survival in appropriately selected patients and is mainly applied to patients with metastastic appendiceal or colorectal cancer limited to the peritoneum [18, 19] .
Intraperitoneal monoclonal antibodies
Catumaxomab is a trifunctional bispecifi c antibody that binds to tumour cells expressing human epithelial cell adhesion molecule (EpCAM), known to be expressed in gastric, hepatobiliary, colonic, and other epithelial carcinomas [17] ) and redirects CD3+ T lymphocytes and Fcγ-receptor-positive accessory tumour cells such as macrophages, dendritic cells and natural killer cells to malignant cells [21] . Based on preclinical data simultaneous activation of T cells and accessory immune cells induces a variety of immunological events that ultimately lead to tumour cell elimination by diff erent killing mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), phagocytosis and perforine-dependent lysis [22, 23] . In an international Phase II/III study 258 cancer patients with recurrent symptomatic malignant ascites resistant to conventional chemotherapy were randomised to paracentesis plus catumaxomab administered as an i.p. infusion on days 0, 3, 7 and 10 or paracentesis alone. Independent of the type of tumour the puncture free survival was signifi cantly longer in the catumaxomab group (median 46 days) than the control group (median 11 days) (hazard ratio = 0.254: p < 0.0001) [24] . Related to the immunological mode of action the most commonly reported adverse events are cytokine release-related symptoms (pyrexia, nausea and vomiting), which are generally mild to moderate and manageable by standard symptomatic treatment [24] . Catumaxomab has been approved in the European Union since April 2009 for the i.p. treatment of malignant ascites in patients with Ep-CAM-positive carcinomas where standard therapy of the underlying malignancy is not available or no longer feasible.
Since VEGF is thought to promote ascites by increasing vascular permeability, preclinical data and reported small series from patients treated off label i.p. with the anti-VEGF antibody bevacizumab support the hypothesis that targeting VEGF may have the potential to prevent local fl uid accumulation [25] . Th erefore, the i.p. application of bevacizumab is currently being investigated in a randomised Phase II trial.
Other investigational therapies
A recently published Phase II study evaluated the treatment with intravenous afl ibercept in 16 patients with advanced chemo-resistant ovarian cancer and symptomatic malignant ascites. Th e fusion protein, designed to bind to VEGF-A, VEGF-B, and placental growth factor (PIGF) signifi cantly reduced the interval between repeat paracenteses. Th e safety profi le was consistent with that reported for anti-VEGF agents [26] .
Up to now further novel approaches have only been studied only in small series. Improvement in ascites is reported in response to cytokine therapy with i.p. α or β interferon, tumour necrosis factor α or infectious agents such as intracavitary Corynebacterium parvum. Also i.p. gold isotope (198Au), chromic phosphate colloid (32ChrP) and matrix metalloproteinase inhibitors were investigated in Phase I/II trials [11] . Taken together, these treatments must be considered as highly experimental and should not be applied outside clinical trials.
Conclusion
Th e management of malignant ascites is a signifi cant challenge in medical oncology. Although diuretics, paracentesis, peritoneal drains and venous shunts are widely used procedures, evidence is weak and randomised controlled trials identifying optimal therapy are lacking. Newer therapies are emerging and await further study. Th e i.p. application of the approved trifunctional antibody catumaxomab seems to be a promising approach, its successful implementation in daily clinical practice has nevertheless to be proven in the future. Since no evidence-based guidelines exist, the diff erent treatment options should be applied with the goal of palliation of symptoms that is best suited for the individual patient.
Take home message
Repeated therapeutic paracenteses yield good, although temporary relief of symptoms. Available data about diuretics are confl icting. Intraperitoneal monoclonal antibodies are a new promising approach.
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